Assessment of platelet activation in several different anticoagulants by the Advia 120 Hematology System, fluorescence flow cytometry, and electron microscopy

Summary

In vivoplatelet activation results are often confounded by activation induced in vitroduring the preparative procedures. We measured ex vivo(basal) and in vitro(thrombin-induced) platelet activation in sodium citrate, ethylenediaminetetraacetic acid (EDTA), and Citrate Theophylline Dipyridamole Adenosine (CTAD) whole blood specimens. Determinations were made by measurements of platelet density (mean platelet component: MPC concentration) on the Advia 120 Hematology System. The MPC has been previously shown to correlate with a fluorescence flow cytometric method, also determined in this study, using the surface expression of CD62P. Moreover, platelet shape and structure changes in EDTA and CTAD anticoagulated whole blood specimens were characterized by transmission electron microscopy (TEM). Observations made using the Advia 120 Hematology System platelet density parameter, MPC, in the absence of thrombin were 25.7 ± 0.9 g/dl, 27.9 ± 0.9 g/dl and 24.8 ± 1.2 g/dl in sodium citrate, EDTA and CTAD whole blood specimens, respectively. Addition of thrombin induced a significant change in platelet MPC for sodium citrate (21.9 ± 1.9 g/dl; p<0.0001) and EDTA (23.2 ± 0.9 g/dl; p<0.0001) whole blood specimens. In contrast, thrombin had no effect on MPC measured in whole blood taken into CTAD tubes. In vitrofluorescence flow cytometric platelet activation experiments measuring the percentage of platelets expressing anti-CD62P showed increase in sodium citrate specimens from 9.2 ± 7.0 to 55.5 ± 23.1 % (p<0.0001) and in EDTA specimens from 1.9 ± 1.7 to 64.6 ± 12.4 % (p<0.0001) after addition of thrombin. However, in blood taken into CTAD tubes, there was no significant change. Studies on platelets isolated from whole blood in CTAD showed activation by thrombin indicating that platelets in CTAD, while protected in its presence remained functional upon its removal. When observed by TEM over time, platelets in EDTA appear more activated and contain fewer granules than platelets in CTAD. We conclude that CTAD demonstrates in vitroplatelet activation inhibition and may be useful in stabilizing ex vivoplatelet activation. The novel platelet activation parameter, MPC, measured by an automated routine hematology system, using customized proprietary software, may be used in conjunction with CTAD, a stabilizing anticoagulant, to measure the ex vivoplatelet activation state in whole blood specimens. TEM studies verify shape modifications and simultaneous retention of intracellular granules at early post-venipuncture time periods in CTAD specimens.

Keywords

Platelets - activation - anticoagulants - Advia 120 - CD62P

• References

• 1 George JN, Thio LL, Morgan RK. Quantitative analysis of platelet membrane glycoproteins: effect of platelet washing procedures and isolation of platelet density subpopulations. Thromb Res 1981; 23: 69-77.
• 2 Hawiger J. Platelet secretory pathways: An overview. Methods Enzymol 1989; 169: 191-5.
• 3 Schmitz G, Rothe G, Ruf A. et al European Working Group on Clinical Cell Analysis: consensus protocol for the flow cytometric characterization of platelet function. Thromb Heamost 1998; 79: 885-96.
• 4 National Committee for Clinical Laboratory Standards. Evacuated tubes and additives for blood specimen collection approved standard. NCCLS Document H1-A4 4th ed. NCCLS Villanova, PA 1996
• 5 Kèhne T, Hornstein A, Semple J. et al Flow cytometric evaluation of platelet activation in blood collected into EDTA vs. Diatube H, a sodium citrate solution supplemented with theophylline, adenosine, and dipyridamole. Am J Hematol 1995; 50: 40-5.
• 6 Golanski J, Pietrucha T, Baj Z. et al Molecular insights into the anticoagulant-induced spontaneous activation of platelets in whole blood-various anticoagulants are not equal. Thromb Res 1996; 83: 199-216.
• 7 McCarthy DA, Macey MG. Novel anticoagulants for flow cytometric analysis of live leukocytes in whole blood. Cytometry 1996; 23: 196-204.
• 8 Ray MJ, Carroll PA, Just SJ. et al A low volume container suitable for monitoring the aPTT of heparinized patients. Blood Coagul Fibrinolysis 1993; 4: 805-7.
• 9 Escolar G, White JG. Changes in glycoprotein expression after platelet activation: differences between in vitro and in vivo studies. Thromb Haemost 2000; 83: 371-86.
• 10 Michelson AD. Platelet activation by throm-bin can be directly measured in whole blood through the use of the peptide GPRP and flow cytometry: Methods and clinical applications. Blood Coagul Fibrinolysis 1994; 5: 121-31.
• 11 Chapman ES, Sorette M, Hetherington E. et al A rapid, automated flow cytometric method to measure activated degranulated platelets by density determination. Thromb Haemost 2003; 89: 1004-15.
• 12 Macey MG, Carty E, Webb L. et al Use of mean platelet component to measure platelet activation on the Advia 120 haematology system. Cytometry 1999; 38: 250-5.
• 13 Pujol-Moix N, Hernèndez A, Escolar G. et al Platelet ultrastructural morphometry for diagnosis of partial -storage pool disease in patients with mild platelet dysfunction and/or thrombocytopenia of unknown origin. Study of 24 cases. Haematologica 2000; 85: 620-7.
• 14 Kunicka JE, Fischer G, Murphy J. et al Improved platelet counting using two-dimensional laser light scatter. Am J Clin Pathol 2000; 114: 283-9.
• 15 Corash L, Tan H, Gralnick H. Heterogeneity of human whole blood platelet subpopulations. I. relationship between buoyant density, cell volume and ultrastructure. Blood 1977; 49: 71-87.
• 16 Mezzano D, Hwang K, Catalano P. et al Evidence that platelet buoyant density, but not size, correlated with platelet age in man. Am J Hematol 1981; 11: 61-76.
• 17 Ruf A, Patscheke H. Flow cytometric detection of activated platelets: comparison of determining shape change, fibrinogen binding, and P-selectin expression. Semin Thromb Hemost 1995; 21: 146-51.
• 18 White JG, Escolar G. EDTA-induced changes in platelet structure and function: adhesion and spreading. Platelets 2000; 11: 56-61.
• 19 Neufeld M, Nowak-Gottl U, Junker R. Citrate-Theophylline-Adenosine-Dipyridamole buffer is preferable to citrate buffer as an anticoagulant for flow cytometric measurements of platelet activation. Clin Chem 1999; 45: 2030-3.
• 20 Mills DCB. The role of cyclic nucleotides in platelets. In: Cyclic nucleotides Part II. Physiology and Pharmacology. Springer-Verlag: Kebabian JW, Nathanson JA (eds) Berlin; 1982: 723-61.
• 21 Gresele P, Arnout J, Deckmyn H. et al Mechanism of the anti-platelet action of dipyridamole in whole blood: Modulation of adenosine concentration and activity. Thromb Haemost 1986; 55: 12-17.
• 22 Feohtistov IA, Paul S, Hollister AS. et al Role of cyclic AMP in adenosine inhibition of intracellular calcium rise in human platelets. Comparison of adenosine effects on thrombin-and epinephrine-induced platelet stimulation. Am J hypertension 1992; 5: 147S-153S.
• 23 Michelson AD, Barnard MR, Krueger LA. et al Evaluation of platelet function by flow cytometry. Methods 2000; 21: 259-70.